Individualizing high-dose oral busulfan: Prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies

Bone Marrow Transplantation

Volumn 26, Issue 5, 2000, Pages 463-470

  Tran, H T ^a   Madden, T ^a   Petropoulos, D ^a   Worth, L L ^a   Felix, E A ^a   Sprigg Saenz, H A ^a   Choroszy, M ^a   Danielson, M ^a   Przepiorka, D ^b   Chan, K W ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Allogeneic stem cell transplantation; Busulfan; Individualized dosing; Pharmacokinetic

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; LORAZEPAM; MESNA; METHOTREXATE; PHENYTOIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOTRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CHRONIC GRANULOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG MEGADOSE; ESOPHAGITIS; FEMALE; FOLLOW UP; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERBILIRUBINEMIA; HYPERPIGMENTATION; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIVER VEIN OBSTRUCTION; MALE; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SEIZURE; SKIN EXFOLIATION; STOMATITIS; VOMITING;

EID: 0033832458     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702561     Document Type: Article

References (29)

1. Busulfan disposition in children
2. Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation
3. Busulfan kinetics and limited sampling model in children with leukemia and inherited disorders
4. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia
5. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?
6. Optimization of busulfan dosage in children undergoing bone marrow transplantation: A pharmacokinetic study of dose escalation
7. Busulfan bioavailability
8. Dose-dependent neurotoxicity of high-dose busulfan in children: A clinical pharmacological study
9. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation
10. Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation
11. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics
12. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients
13. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation
14. Busulfan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens
15. Association of busulfan under the curve with veno-occlusive disease in patients following BMT
16. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation
17. Geometric method for measuring body surface area with height-weight formula validated in infants, children and adults
18. Allogeneic transplantation for advanced leukemia: Improved short-term outcome with blood stem cell grafts and tacrolimus
19. Regimen-related toxicity in patients undergoing bone marrow transplantation
20. Veno-occlusive disease of the liver following bone marrow transplantation
21. Development of a single probe for documentation of chimerism following bone marrow transplantation
22. Measurement of busulfan in plasma by high-performance liquid chromatography
23. A program package for simulation and parameter estimation in pharmacokinetics
24. Chronopharmacology of high-dose busulfan in children
25. An improved limited sampling method for individualized busulfan dosing in bone marrow transplantation in children
26. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology
27. Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice
28. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic bone marrow transplantation in advanced acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels
29. Phase I-II study of i.v. busulfan/cyclophosphamide (BUCY) as stem cell transplantation conditioning therapy